> Research Use Only Disclaimer: GHRP-6 is a research peptide not approved by the FDA for human use. All dosing information, protocols, and data in this article are derived from peer-reviewed scientific literature and are provided strictly for educational and research purposes only. This article does not constitute medical advice. Do not administer GHRP-6 or any research peptide to humans.
---
# GHRP-6 Dosage Protocol Guide 2026: Reconstitution, Timing & Appetite Effects
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and the founding member of the GHRP family of growth hormone secretagogues. Unlike its newer counterparts — GHRP-2, Ipamorelin, and Hexarelin — GHRP-6 carries a uniquely pronounced appetite-stimulating effect that researchers must account for when designing protocols. This guide covers everything a researcher needs to know about GHRP-6 reconstitution, dosing ranges, injection timing, and the mechanisms behind its distinctive ghrelin-mimetic profile.
---
What Is GHRP-6? A Brief Research Overview
GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) that acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a). It was the first peptide in the GHRP class characterized in research settings, making it the reference compound against which all subsequent GHRPs — GHRP-2, Ipamorelin, Hexarelin — were benchmarked.
Key pharmacological properties:
- •Receptor: GHS-R1a agonist (primary), mild ghrelin mimetic
- •Mechanism: Stimulates pituitary GH release via GHS-R1a; also blocks somatostatin
- •GH pulse amplitude: Moderate-to-strong (similar to GHRP-2, weaker than Hexarelin)
- •Appetite effect: Pronounced — the strongest appetite stimulation among GHRPs
- •IGF-1 elevation: Indirect, via sustained GH release
The defining characteristic of GHRP-6 in research is its dual action on GHS-R1a and partial ghrelin pathway activation. This produces a robust hunger signal that researchers using GHRP-2 or Ipamorelin rarely encounter at equivalent doses.
---
GHRP-6 Reconstitution Protocol
Standard Vial Sizes
GHRP-6 is most commonly supplied in 5mg lyophilized powder vials. Some suppliers also offer 2mg and 10mg vials. The reconstitution process is identical regardless of vial size — only the target concentration changes.
Recommended Diluent
Use bacteriostatic water (BW) — sterile water containing 0.9% benzyl alcohol — for multi-use vials. Bacteriostatic water inhibits bacterial growth and allows the reconstituted peptide to be stored safely for 28–30 days under refrigeration. Do not use plain sterile water for multi-dose research protocols.
Reconstitution Table — 5mg Vial
| Target Concentration | BW to Add | Resulting Dose per 0.1mL (10 units on U-100 syringe) |
|---|---|---|
| 2 mg/mL | 2.5 mL | 200 mcg |
| 2.5 mg/mL | 2.0 mL | 250 mcg (most common research concentration) |
| 5 mg/mL | 1.0 mL | 500 mcg |
| 10 mg/mL | 0.5 mL | 1,000 mcg |
Reconstitution procedure:
1. Allow the vial to reach room temperature before reconstituting.
2. Draw the bacteriostatic water into a sterile insulin syringe.
3. Inject the BW slowly down the inside wall of the vial — do not spray directly onto the powder.
4. Gently swirl (do not shake) until the lyophilized powder dissolves completely.
5. Inspect for clarity: the solution should be colorless and free of particulates.
6. Label the vial with date reconstituted and store at 2–8°C (refrigerator).
> For a step-by-step walkthrough with volume calculations, see the Peptide Reconstitution & Dosage Calculator. For GHRP-6's full research profile, pricing, and supplier comparison, see /peptide/ghrp-6.
---
GHRP-6 Research Dosing Ranges
Standard Research Dose
Scientific literature documents GHRP-6 administered in the range of 100–300 mcg per injection, with most research protocols using 100 mcg three times daily as a baseline. The 100 mcg dose has been shown in multiple human studies to produce near-maximal GH release — doses above 200–300 mcg show diminishing returns in GH output (the GH response plateaus, or "bells out").
Dosing Schedule — Research Reference Table
| Protocol Tier | Dose Per Injection | Injections/Day | Total Daily Dose | Notes |
|---|---|---|---|---|
| Low | 100 mcg | 2x | 200 mcg | Baseline GH stimulus; minimal appetite effect |
| Standard | 100 mcg | 3x | 300 mcg | Most common research protocol |
| Higher | 200 mcg | 2–3x | 400–600 mcg | Stronger GH pulse; appetite effect more pronounced |
| Upper | 300 mcg | 3x | 900 mcg | Research-only; used to assess ceiling dose effects |
Saturation Dose Concept
GHRP-6 exhibits a well-documented saturation kinetic: approximately 1 mcg/kg body weight per injection approaches maximal GH secretion in human research subjects. For a 100 kg subject, this corresponds to approximately 100 mcg per injection. Doses above this threshold produce marginal additional GH output in most subjects, making the 100–200 mcg range the most studied.
---
Timing Protocols — The Critical Food Interaction
This is the most important operational consideration for GHRP-6 research protocols.
Unlike Ipamorelin or GHRP-2 — which have milder appetite effects — GHRP-6 produces a strong ghrelin-like hunger signal that is significantly amplified by postprandial insulin or glucose elevations. Administering GHRP-6 within 30–60 minutes of eating substantially blunts the GH response.
Timing Rules for GHRP-6 Research
| Window | Guideline |
|---|---|
| Pre-injection fast | Minimum 2 hours after last meal (3 hours preferred) |
| Post-injection fast | Minimum 30 minutes after injection before eating |
| Carbohydrate impact | High-GI meals reduce GH response more than high-fat or high-protein meals |
| Insulin interaction | Elevated insulin from a meal competes with GHRP-6-stimulated GH release |
Recommended Daily Injection Windows (3x per day protocol)
1. Morning (on waking, fasted) — ideal; cortisol/GH axis is primed in the early morning fasted state
2. Midday (minimum 2–3 hours post-breakfast) — ensure last meal has cleared
3. Pre-sleep (before bed, minimum 2–3 hours after dinner) — sleep-associated GH pulse is a major research target
This three-injection structure maximizes the number of distinct GH pulses observed per day in research settings.
---
The Appetite Stimulation Mechanism — What Makes GHRP-6 Unique
GHRP-6's most distinctive feature in research is its pronounced orexigenic (appetite-stimulating) effect. Understanding why this happens — and why it differs from other GHRPs — is essential for designing protocols.
Ghrelin Pathway Activation
GHRP-6 structurally mimics ghrelin, the endogenous "hunger hormone" produced in the stomach. When GHRP-6 binds GHS-R1a in the hypothalamus and pituitary, it activates the same downstream signaling cascade as ghrelin, which includes:
- •Activation of neuropeptide Y (NPY) and Agouti-related peptide (AgRP) neurons in the arcuate nucleus
- •Inhibition of POMC (pro-opiomelanocortin) neurons, which normally suppress appetite
- •Direct stimulation of gastric motility and gastric acid secretion
The net effect: subjects in research settings consistently report strong hunger within 20–45 minutes of administration. This is not a side effect unique to high doses — it occurs reliably at the 100 mcg research dose.
GHRP-6 vs Other GHRPs: Appetite Comparison
| GHRP | Appetite Stimulation | Mechanism |
|---|---|---|
| GHRP-6 | Pronounced (strongest) | Dual GHS-R1a + ghrelin pathway activation |
| GHRP-2 | Moderate | GHS-R1a agonist; minimal ghrelin mimicry |
| Hexarelin | Mild-to-moderate | High GHS-R1a potency; less ghrelin mimicry |
| Ipamorelin | Minimal | Selective GHS-R1a; no ghrelin mimicry |
For researchers where appetite stimulation is an undesired confounding variable, Ipamorelin is typically preferred due to its near-complete selectivity for GHS-R1a without the ghrelin-pathway hunger signal.
For researchers studying the appetite-GH axis interaction, GHRP-6's unique profile makes it the preferred research compound.
---
Cortisol and Prolactin: What Research Shows
GHRP-6, like most first-generation GHRPs, produces measurable elevations in cortisol and prolactin alongside GH. This is an important variable in research design.
Research Data Summary
| Hormone | GHRP-6 Effect | Typical Magnitude |
|---|---|---|
| GH (growth hormone) | Strongly elevated | 4–15x baseline (dose-dependent) |
| IGF-1 | Moderately elevated | Proportional to sustained GH exposure |
| Cortisol | Elevated | ~30–50% above baseline at 100 mcg |
| Prolactin | Elevated | Variable; typically 20–40% above baseline |
| ACTH | Mildly elevated | Downstream of cortisol response |
These hormonal co-elevations are reduced — but not eliminated — at lower doses (100 mcg vs 300 mcg). Compared to GHRP-2 and Hexarelin, GHRP-6 produces broadly similar cortisol and prolactin elevation patterns. Ipamorelin is notable for producing virtually no cortisol or prolactin elevation, making it the preferred GHRP where hormonal selectivity is the research priority.
---
GHRP-6 vs Ipamorelin: Research Protocol Comparison
| Parameter | GHRP-6 | Ipamorelin |
|---|---|---|
| GH pulse strength | Strong | Moderate |
| Appetite stimulation | Pronounced | Minimal |
| Cortisol elevation | Moderate | Negligible |
| Prolactin elevation | Moderate | Negligible |
| Food timing sensitivity | High | Moderate |
| Selectivity | Lower (ghrelin pathway) | High (GHS-R1a only) |
| Typical research dose | 100–300 mcg | 200–300 mcg |
Researchers comparing GHRPs side by side should review the complete GHRP comparison guide, which covers all four major GHRP compounds with head-to-head protocol data.
---
Storage, Stability, and Handling
Lyophilized (Powder) Form
Lyophilized GHRP-6 is highly stable when stored correctly:
- •Short-term (up to 6 months): Refrigerated at 2–8°C
- •Long-term (up to 24 months): Frozen at -20°C or below
- •Protect from light and humidity
- •Avoid repeated freeze-thaw cycles — aliquot if long-term frozen storage is planned
Reconstituted Form (in Bacteriostatic Water)
- •Stable for 28–30 days at 2–8°C after reconstitution
- •Do not freeze reconstituted solution
- •Discard if solution appears cloudy, discolored, or particulate
- •Use sterile technique at all times when drawing doses
---
Sample Research Protocol: 8-Week GHRP-6 Schedule
The following is an example framework drawn from published literature, provided for reference purposes only.
Compound: GHRP-6
Dose per injection: 100 mcg
Frequency: 3x daily (morning, midday, evening)
Total daily dose: 300 mcg
Duration: 8 weeks (common cycle length in published research)
Protocol notes:
- •Morning injection: fasted, upon waking
- •Midday injection: minimum 2 hours post-meal
- •Evening injection: minimum 2–3 hours after last meal, before sleep
- •Consume a meal 30–60 minutes after each injection if appetite stimulation is part of the research endpoint
- •Avoid high-GI carbohydrates immediately pre-injection to preserve GH response
Combination research: GHRP-6 is frequently co-administered with GHRH analogs (Sermorelin, CJC-1295, CJC-1295 No DAC) in research, as these two classes act synergistically — GHRH increases pituitary GH production while GHRP-6 simultaneously blocks somatostatin and stimulates GH release through GHS-R1a. The synergy is well-documented in the literature and represents one of the most studied peptide combinations.
---
Frequently Asked Questions
Can GHRP-6 be combined with a GHRH analog?
Yes. GHRP-6 + GHRH combinations are among the most extensively studied peptide stacks in GH research. The two compounds act synergistically, with published studies reporting GH response 2–10x greater than either alone.
Why is GHRP-6 less popular than Ipamorelin in modern research?
Ipamorelin's high selectivity — GH release with virtually no cortisol, prolactin, or appetite side effects — makes it a cleaner research variable in most study designs. GHRP-6 remains the compound of choice specifically when appetite stimulation or ghrelin-pathway research is the endpoint.
Does GHRP-6 cause desensitization?
Research suggests receptor desensitization can occur with very frequent dosing. Standard protocols using 2–3 injections daily appear to preserve receptor sensitivity across typical study durations.
What is the difference between GHRP-6 and Hexarelin?
Hexarelin is structurally derived from GHRP-6 but is significantly more potent at GHS-R1a. Hexarelin also binds the CD36 scavenger receptor (cardiac protection research) and shows GH response approximately 2–3x stronger than GHRP-6 at equivalent doses, with less appetite stimulation.
---
Summary
GHRP-6 remains a foundational research compound in growth hormone secretagogue studies. Its key research characteristics:
- •Strong GH pulse via GHS-R1a agonism and somatostatin suppression
- •Pronounced appetite stimulation — the defining feature distinguishing it from second-generation GHRPs
- •Standard research dose: 100–300 mcg per injection, 2–3x daily
- •Critical timing requirement: Administer in a fasted state (≥2 hours post-meal) to preserve GH response
- •Reconstitution: 5mg vial + 2.0 mL bacteriostatic water = 2.5 mg/mL working concentration
For researchers where the appetite effect is a confound, Ipamorelin or GHRP-2 are typically preferred. For researchers studying the ghrelin-GH axis, GHRP-6's unique pharmacological profile makes it irreplaceable.
---
> For Research Use Only. GHRP-6 is not approved by the FDA for therapeutic use in humans. Information in this guide is provided for educational purposes only and is not medical advice. All research use must comply with applicable institutional review and regulatory requirements.